Anthem Blue Cross and Blue Shield | CommercialAugust 1, 2023
Clinical Criteria updates for specialty pharmacy are available
Effective for dates of service on and after November 1, 2023, the following Clinical Criteria were developed and could mean that services previously covered may now be considered not medically necessary.
For Anthem Blue Cross and Blue Shield and its affiliate HealthKeepers, Inc., prior authorization(PA) of these specialty pharmacy drugs will be managed by Anthem. Drugs used for the treatment of oncology will still require PA by Carelon Medical Benefits Management, Inc.*
For more information, access the Clinical Criteria document information.
CC-0057 | Krystexxa (pegloticase) |
CC-0068 | Growth Hormone |
CC-0225 | Tzield (teplizumab-mzwv) |
CC-0240 | Zynyz (retifanlimab-dlwr) |
* Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of Anthem Blue Cross and Blue Shield and its affiliate HealthKeepers, Inc.
VABCBS-CM-028323-23
PUBLICATIONS: August 2023 Provider Newsletter
To view this article online:
Or scan this QR code with your phone